Nolato Medical Expands Its Operations in China

Regulatory News:

Nolato (STO:NOLAB) is expanding its Chinese production facility with an additional 2,200 square metres, of which around 800 square metres will be clean room of the highest standard in accordance with ISO 14644-1:1999, class 8.

"China is the fastest growing market for pharmaceuticals and medical devices, which means that more and more of our customers are discussing expanded production in China for the Asian market,” says Christer Wahlquist, President of the Nolato Medical business area. The expansion, which will accommodate around 30 injection moulding machines, is being made to allow us to stay one step ahead of our customers and secure resources for future growth in China.

"Our philosophy is to be a close, long-term and reliable partner who can offer our customers global development and production facilities. The new facility will satisfy even the most demanding requirements of our customers,” Christer Wahlquist adds.

Nolato Medical has been active in China since 2008. Overall, Nolato Medical has around 25,000 square metres of clean room capacity in a range of classes at nine facilities in Asia, Europe and North America.

-----

The Nolato Group is a high-tech developer and manufacturer of polymer product systems for leading customers in medical devices, telecommunications, hygiene, automotive products and other selected industrial sectors. Nolato’s shares are quoted on the NASDAQ OMX Nordic Exchange, Stockholm Mid Cap segment, where they are included in the Industrial sector. www.nolato.se

The Nolato Medical business area has sales of approximately SEK 1.2 billion and nearly 1,000 employees at units in Sweden, Great Britain, Hungary, USA and China.

The information contained in this press release is the information which Nolato must make public in accordance with the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication July 2, 2013, at 8.25am.

This information was brought to you by Cision http://news.cision.com